Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02996539
Other study ID # FirstPHKunming
Secondary ID
Status Completed
Phase N/A
First received November 24, 2016
Last updated December 14, 2016
Start date February 2013
Est. completion date April 2015

Study information

Verified date December 2016
Source First People's Hospital of Kunming
Contact n/a
Is FDA regulated No
Health authority China: Ministry of Health
Study type Observational

Clinical Trial Summary

Several studies have investigated an association between cardiac autonomic neuropathy (CAN) and albuminuria, glomerular filtration rate, or both, and hypothesized that CAN is involved in the pathogenesis of nephropathy. However, most of these studies had focused on Caucasians and were limited to a small number of patients with type 1 diabetes mellitus, or had used a conventional Ewing battery of tests based on dynamic cardiovascular maneuvers.Yet, there is consistent data showing that Asian diabetic populations, including the Chinese, have a higher risk of renal complications than Caucasians do.

The present study investigated an association between heart rate variability (HRV) parameters and diabetic kidney disease (DKD) in Chinese type 2 diabetes mellitus (T2DM) patients, specifically through time and frequency domain analyses of HRV and urine albumin creatinine ratio (UACR) or estimated glomerular filtration rate (eGFR).


Description:

present study investigated an association between HRV parameters and DKD in Chinese T2DM patients, specifically through time and frequency domain analyses of HRV and UACR or eGFR


Recruitment information / eligibility

Status Completed
Enrollment 392
Est. completion date April 2015
Est. primary completion date April 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Clinical diagnosis of T2DM

- Adult patients has had consecutively undergone 24-hour Holter monitoring for heart rate variability analysis

Exclusion Criteria:

- Patients with acute complications of DM including diabetic ketoacidosis, hyperosmolar coma

- Foot ulcer

- Severe acute or chronic infection

- Chronic liver disease

- Dialysis or renal transplantation

- The presence of any serious concomitant disease affecting life expectancy were not eligible for the study.

Study Design

Observational Model: Case-Only


Intervention

Other:
Clinical examination and laboratory measurements
Subjects were interviewed by a physician regarding their medical history, history of hypoglycemic attacks, smoking status, and alcohol consumption. Concentrations of blood urea nitrogen (BUN) and serum creatinine (SCr) were analyzed by the urease-ultraviolet rate method and picric acid method, respectively. Serum uric acid was determined using the enzymatic colorimetric method. Serum hemoglobin A1c (HbA1c) was measured by liquid enzymatic assay. Urine albumin and urine creatinine were found through immune turbidimetric analysis and the enzymatic method, respectively.

Locations

Country Name City State
China Internal medicine department, Kunming First People's Hospital Kunming Yunnan

Sponsors (1)

Lead Sponsor Collaborator
Shi wei, MM

Country where clinical trial is conducted

China, 

References & Publications (1)

Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014 Oct;37(10):2864-83. doi: 10.2337/dc14-1296. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Association between HRV and renal function (eGFR and UACR) Assessment of HRV HRV measurement based on 24-hour ambulatory ECG monitoring was obtained from all patients using a 3- channel digital Holter recorder (CB-2302-A, Wuxi, Jiangsu, China). Assessment of DKD DKD was defined as the presence of albuminuria (UACR = 30 mg/g,urine albumin in milligram,creatinine in gram) or eGFR < 60 mL/min/1.73 m^2 (creatinine concentration in umol/l,creatinine molecular weight in micromole, volume in litre;urine volume per minute in milliliter per minute; body surface area in square meter) based on SCr levels. Albuminuria was defined using UACR of a single early-morning urine measurement.For all Participants, 132 patients had albuminuria and 50 patients with eGFR < 60 mL/min/1.73 m^2 1week No
Secondary Clinical characteristics of patients Clinical examination and laboratory measurements Subjects were interviewed by a physician regarding their medical history, history of hypoglycemic attacks, smoking status, and alcohol consumption. A trained examiner measured the height (in meters) and body weight (in kilograms) of the patients. Body mass index (BMI) in kg/m^2, weight in kilograms, height in meters. Hypertension was defined as systolic blood pressure =140 mm Hg or diastolic blood pressure =90 mm Hg, or both, or if the patient was already taking anti-hypertensive drugs. Blood and urine samples were analyzed at the medical examination center of Kunming First People's Hospital. 1week No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04082091 - Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
Active, not recruiting NCT02248311 - "Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population N/A
Completed NCT02653300 - A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH) Phase 2
Completed NCT03655535 - Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes Phase 2
Completed NCT03256747 - Effects of Neuromuscular Electrical Stimulation on Glucose Variability in Patients With Type 2 Diabetes N/A
Completed NCT05343767 - Investigate the Efficacy and Safety of Low-Glu in Patients Newly Diagnosed With Type II Diabetes Mellitus N/A
Withdrawn NCT03675074 - Neujia Anastomosis for Treatment of Obesity and Type II Diabetes N/A
Withdrawn NCT03190798 - Effects of Canagliflozin on Intravascular Volume and Hemodynamics Phase 4
Active, not recruiting NCT03437330 - Empagliflozin Effect on Glucose Toxicity Phase 4
Withdrawn NCT03008395 - Empowerment, Motivation and Medical Adherence (EMMA). N/A
Not yet recruiting NCT05539066 - AI Health Assistant and Type 2 Diabetes N/A
Completed NCT03682445 - Metabolic, Physical Responses To Exercise In Patients With Type 2 Diabetes Mellitus N/A
Not yet recruiting NCT03239119 - The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus Phase 3
Completed NCT03259789 - Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects Phase 3
Recruiting NCT03506230 - Financial Incentives for Low Socioeconomic Diabetic Patients N/A
Completed NCT03072407 - MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM Phase 1
Completed NCT05668442 - Feasibility of an Online Exercise Community Among Individuals With Type 2 Diabetes
Completed NCT02956044 - Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin Phase 1
Completed NCT02964572 - Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes N/A
Completed NCT02628392 - A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM) N/A

External Links